扫码关注科兴官方微信号“疫苗之益”

R&D Platform

The company always attaches great importance to R&D and innovation. At present, the company has a research and development team of more than 150 people, the proportion of masters and doctors is about 70%, and has introduced many overseas high-level talents. The company has a national-level post-doctoral scientific research workstation, and has established cooperative relationships with many universities, institutes, and scientific research institutions at home and abroad.


MetInfo enterprise content manager system | MetInfo CMS


The company has the production and R & D capacity of inactivated virus vaccines, attenuated vaccines and bacterial vaccines. And It has established virus isolation, strain isolation, human diploid cell isolation and construction, genetic engineering bacteria construction, bacterial fermentation tank technology, large-scale cell factory culture, cell microcarrier fermentation, virus fermentation culture, virus purification, protein purification, polysaccharide purification, proteoglycan incorporation, traditional aluminum adjuvant technology, new aluminum adjuvant technology, preparation of quality control and verification methods, immunogenicity and protective evaluation, monoclonal antibody preparation and more than 20 technical platforms ,having strong research and development and innovation capabilities.


MetInfo enterprise content manager system | MetInfo CMS